Our prospective data indicate that rituximab is well tolerated and active in patients with WM. Previously untreated and pretreated patients seem to benefit equally. Repeat 4-week courses of rituximab may prolong the duration of response of the disease, but this observation requires confirmation in prospective, randomized trials. Furthermore, studies that will combine rituximab with chemotherapy may be relevant.
Meletios A Dimopoulos, Raymond Alexanian, Dimitra Gika, Athanasios K. Anagnostopoulos, Constantinos Zervas, Athanassios Zomas, Marie Christine Kyrtsonis, Nicolaos Anagnostopoulos, Gerassimos A. Pangalis, Donna M. Weber
Athanasios K. Anagnostopoulos, Steven P. Treon, Konstantinos Zervas, Andrew R. Branagan, Dimitra Gika, Athanasios Zomas, Marie Christine Kyrtsonis, Amalia Vassou, Nikolaos Anagnostopoulos, Gerasimos Pangalis, Meletios A Dimopoulos
Discussion(0)
No comments yet. Be the first to comment.